Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / May 6, 2020 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS) of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action...
SAN DIEGO, CA / ACCESSWIRE / May 5, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ:GOSS shares. Investors, who purchased shares of Gossamer Bio, Inc. (NASDAQ:GOSS), have certain options and should contact the Shareholders Foundati...
Adaptimmune (NASDAQ: ADAP ) initiated with Neutral rating and $3 (17% downside risk) price target at Mizuho Securities. More news on: Adaptimmune Therapeutics plc, Autolus Therapeutics plc, Atreca, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
San Diego, California--(Newsfile Corp. - April 20, 2020) - The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: GOSS shares. Investors, who purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS), have certain options and should contact the...
New York, New York--(Newsfile Corp. - April 17, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities...
New York, New York--(Newsfile Corp. - April 14, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal secu...
SAN DIEGO, April 08, 2020 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Gossamer Bio, Inc. (NASDAQ: GOSS). Investors, who purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS), have certain options and should co...
New York, New York--(Newsfile Corp. - April 7, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal secur...
NEW YORK, April 06, 2020 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) in the United States District Court for the Southern District o...
New York, New York--(Newsfile Corp. - April 3, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-24 17:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for GOSS on June 24, 2024 04:04PM ET. The previous analyst recommendation was Buy. GOSS was trading at $0.8261 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present up...
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet ...